Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV001277783 | SCV002814436 | uncertain significance | Pontocerebellar hypoplasia type 2D | 2021-08-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002537772 | SCV003476882 | pathogenic | not provided | 2023-12-19 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu464*) in the SEPSECS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 38 amino acid(s) of the SEPSECS protein. This variant is present in population databases (rs747732980, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with SEPSECS-related conditions. ClinVar contains an entry for this variant (Variation ID: 989880). This variant disrupts a region of the SEPSECS protein in which other variant(s) (p.Glu477*) have been determined to be pathogenic (Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Natera, |
RCV001277783 | SCV001464752 | uncertain significance | Pontocerebellar hypoplasia type 2D | 2020-08-13 | no assertion criteria provided | clinical testing |